US 12,258,407 B2
Anti-PD-1 antibodies, dosages and uses thereof
Lieping Chen, Beijing (CN); and Liqun Luo, Beijing (CN)
Assigned to Tayu Huaxia Biotech Medical Group Co., Ltd., Beijing (CN)
Appl. No. 17/260,974
Filed by Tayu Huaxia Biotech Medical Group Co., Ltd., Beijing (CN)
PCT Filed Jul. 19, 2019, PCT No. PCT/CN2019/096679
§ 371(c)(1), (2) Date Jan. 15, 2021,
PCT Pub. No. WO2020/015722, PCT Pub. Date Jan. 23, 2020.
Claims priority of application No. PCT/CN2018/096206 (WO), filed on Jul. 19, 2018.
Prior Publication US 2021/0261665 A1, Aug. 26, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/28 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/2818 (2013.01) [A61K 2039/505 (2013.01); A61K 2039/545 (2013.01); C07K 2317/52 (2013.01); C07K 2317/565 (2013.01)] 21 Claims
 
1. A method of treating a cancer in a human patient in need thereof, comprising administering to the patient one or more doses of an isolated antibody or fragment thereof having specificity to a human programmed cell death protein 1 (PD-1), wherein the antibody comprises a heavy chain variable region comprising heavy chain complementarity determining regions HCDR1, HCDR2, and HCDR3, and a light chain variable region comprising light chain complementarity determining regions LCDR1, LCDR2, and LCDR3, wherein:
(a) HCDR1 comprises an amino acid sequence of GFTFSSYT (SEQ ID NO: 1), HCDR2 comprises an amino acid sequence of ISHGGGDT (SEQ ID NO: 2), HCDR3 comprises an amino acid sequence of ARHSGYERGYYYVMDY (SEQ ID NO: 3), LCDR1 comprises an amino acid sequence of ESVDYYGFSF (SEQ ID NO: 4), LCDR2 comprises an amino acid sequence of AAS (SEQ ID NO: 5), and LCDR3 comprises an amino acid sequence of QQSKEVPW (SEQ ID NO: 6);
(b) HCDR1 comprises an amino acid sequence of GYTFTSYT (SEQ ID NO: 7), HCDR2 comprises an amino acid sequence of INPTTGYT (SEQ ID NO: 8), HCDR3 comprises an amino acid sequence of ARDDAYYSGY (SEQ ID NO: 9), LCDR1 comprises an amino acid sequence of ENIYSNL (SEQ ID NO: 10), LCDR2 comprises an amino acid sequence of AAK (SEQ ID NO: 11), and LCDR3 comprises an amino acid sequence of QHFWGTPWT (SEQ ID NO: 12); or
(c) HCDR1 comprises an amino acid sequence of GFAFSSYD (SEQ ID NO: 13), HCDR2 comprises an amino acid sequence of ITIGGGTT (SEQ ID NO: 14), HCDR3 comprises an amino acid sequence of ARHRYDYFAMDN (SEQ ID NO: 15), LCDR1 comprises an amino acid sequence of ENVDNYGINF (SEQ ID NO: 16), LCDR2 comprises an amino acid sequence of VSS (SEQ ID NO: 17), and LCDR3 comprises an amino acid sequence of QQSKDVPW (SEQ ID NO: 18); and
wherein each dose is at least about 1 mg/kg and less than 10 mg/kg.